Related Experiment Video

Updated: Sep 26, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Lipoprotein lipase gene polymorphisms in Croatian patients with coronary artery disease

Goran Ferencak1, Daria Pasalić, Branka Grsković

  • 1Clinical Institute of Laboratory Diagnosis, Clinical Hospital Center and Zagreb University School of Medicine, Zagreb, Croatia. gferen@mef.hr

Clinical Chemistry and Laboratory Medicine
|May 16, 2003
PubMed

Insights

Lipoprotein lipase gene variations influence coronary artery disease (CAD) risk and lipid profiles. The N291S polymorphism showed a significant association with CAD, while other variants impacted lipid levels in Croatian patients.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Biochemistry

Background:

  • Elevated triglycerides and reduced high-density lipoprotein (HDL) are key risk factors for coronary artery disease (CAD).
  • Lipoprotein lipase (LPL) plays a crucial role in lipid metabolism, making its gene a potential target for studying CAD predisposition.
  • Genetic variations in the LPL gene may influence an individual's susceptibility to CAD and their lipid profiles.

Purpose of the Study:

  • To investigate the association between specific LPL gene polymorphisms (-93T/G, D9N, N291S, and S447X) and the risk of CAD.
  • To determine the impact of these LPL gene polymorphisms on lipid levels (triglycerides, HDL, HDL2-cholesterol, apolipoprotein A-I) in Croatian patients with and without confirmed CAD.
  • To explore potential interactions between LPL gene variants, lipid profiles, and CAD risk.

Main Methods:

  • Genotyping of four LPL gene polymorphisms (-93T/G, D9N, N291S, S447X) in Croatian patients.
  • Case-control study design comparing patients with and without angiographically confirmed CAD.
  • Analysis of lipid profiles, including triglycerides, HDL-cholesterol, HDL2-cholesterol, and apolipoprotein A-I levels.
  • Statistical analysis to assess the association between LPL polymorphisms and CAD risk, adjusting for lipid levels.

Main Results:

  • The N291S polymorphism was significantly associated with increased CAD risk (OR = 0.36; p = 0.048), an association moderately affected by lipid adjustment.
  • Non-carriers of the -93T/G and D9N polymorphisms exhibited significantly higher HDL2-cholesterol and apolipoprotein A-I levels within the CAD group.
  • The S447X mutation was linked to lower triglyceride and higher HDL2-cholesterol levels in the control group.
  • No significant differences in lipid levels were observed for the N291S variant between carriers and non-carriers.

Conclusions:

  • LPL gene polymorphisms, particularly N291S, may play a role in the genetic predisposition to coronary artery disease.
  • Specific LPL gene variants are associated with variations in lipid profiles, potentially influencing CAD risk.
  • Further research is warranted to elucidate the complex interplay between LPL genetics, lipid metabolism, and cardiovascular disease development.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...